股本结构
单位:万股
公告日期 | 2024-02-01 | 2024-02-01 | 2023-11-06 | 2023-11-01 | 2023-08-07 | 2023-05-15 |
---|---|---|---|---|---|---|
证券总股本 | 138.06 | 4141.90 | 4147.71 | 4141.90 | 4063.97 | 3743.49 |
普通股本 | 138.06 | 4141.90 | 4147.71 | 4141.90 | 4063.97 | 3743.49 |
优先股 | 未披露 | 未披露 | 未披露 | 9.62 | 9.62 | 未披露 |
其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
变动日期 | 2024-02-05 | 2024-02-01 | 2023-10-23 | 2023-09-30 | 2023-06-30 | 2023-05-15 |
注释:中概股证券总股本=普通股股本/
存托凭证比例
历史变动
公告日期 | 变动后普通股本(万股) | 变动后优先股(万股) | 变动原因 | 变动日期 |
---|---|---|---|---|
2024-02-01 | 138.06 | 未披露 |
更多>>
GT Biopharma, Inc. effect a reverse stock split of common stock, at a ratio of 1-for-30. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024.
|
2024-02-05 |
2024-02-01 | 4141.90 | 未披露 | 定期报告 | 2024-02-01 |
2023-11-06 | 4147.71 | 未披露 | 定期报告 | 2023-10-23 |
2023-11-01 | 4141.90 | 9.62 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock in settlement of accounts payable and accrued expenses
Issuance of common stock to an officer and a board member for services
|
2023-09-30 |
2023-08-07 | 4063.97 | 9.62 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common shares in settlement of vendors payable
Issuance of common stock for exercise of Prefunded Warrants
|
2023-06-30 |
2023-05-15 | 3743.49 | 未披露 | 定期报告 | 2023-05-15 |
2023-05-05 | 3749.31 | 未披露 | 定期报告 | 2023-05-01 |
2023-05-15 | 3688.27 | 9.62 |
更多>>
From December 31, 2022 to March 31, 2023
Private placement of common stock
Issuance of common shares for services
Issuance of common shares in settlement of vendors payable
|
2023-03-31 |
2023-03-30 | 3680.93 | 未披露 | 定期报告 | 2023-03-30 |
2023-01-04 | 3900.76 | 未披露 |
更多>>
Common Stock offered 3,600,000 shares by the company
|
2023-01-04 |
2023-03-30 | 3272.25 | 9.62 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock as equity compensation to consultants
Cancellation of common stock previously issued for services
Issuance of common stock in settlement of vendor payable
Common stock issued upon conversion of notes payable
Cancellation of common stock previously issued to prior CEO
Issuance of common stock as equity compensation to officers, employees, and board of directors
|
2022-12-31 |
2023-01-04 | 3250.76 | 未披露 | 定期报告 | 2022-12-30 |
2022-10-31 | 3255.77 | 未披露 | 定期报告 | 2022-10-31 |
2022-10-31 | 3250.76 | 9.62 |
更多>>
From June 30, 2022 to September 30, 2022
Equity compensation to officers, employees, and board of directors
Issuance of common shares in settlement of vendor payable
Equity compensation to consultants
|
2022-09-30 |
2022-08-17 | 3109.25 | 未披露 | 定期报告 | 2022-08-08 |
2022-08-15 | 3069.36 | 9.62 |
更多>>
From March 31, 2022 to June 30, 2022
Cancellation of common stock upon settlement with former officer
Equity compensation to officers, employees, and board of directors
Issuance of common shares for services
|
2022-06-30 |
2022-05-16 | 3050.07 | 未披露 | 定期报告 | 2022-05-16 |
2022-04-29 | 3308.62 | 未披露 | 定期报告 | 2022-04-18 |
2022-05-16 | 3234.57 | 9.62 |
更多>>
From December 31, 2021 to March 31, 2022
Cancellation of common stock
Issuance of common shares for common shares issuable
Issuance of common shares as equity compensation to officers, employees, and board of directors
Issuance of common shares for services
|
2022-03-31 |
2022-03-28 | 3212.28 | 未披露 | 定期报告 | 2022-03-28 |
2022-03-28 | 3206.20 | 9.62 |
更多>>
From December 31, 2020 to December 31, 2021
Conversion of Preferred Series J-1 to common stock
Common shares issued upon mandatory conversion of notes payable and accrued interest
Common shares issued upon exercise of warrants
Issuance of common stock in public offering, net of cost
Issuance of common stock for research and development agreement
Issuance of common stock for services
Equity compensation to officers, board of directors and employees
|
2021-12-31 |
2021-11-10 | 3058.24 | 未披露 | 定期报告 | 2021-11-12 |
2021-11-10 | 3050.83 | 9.62 |
更多>>
From June 30, 2021 to September 30, 2021
Common shares issued upon conversion of notes payable
Common shares issued upon exercise of warrants
Issuance of common stock for services
Equity compensation to officers and board of directors
|
2021-09-30 |
2021-08-23 | 3048.22 | 未披露 | 定期报告 | 2021-08-15 |
2021-08-23 | 2814.41 | 9.62 |
更多>>
From March 31, 2021 to June 30, 2021
Common shares issued upon conversion of notes payable
Common shares issued upon exercise of warrants
Issuance of common stock for services
Equity compensation to officers and board of directors
|
2021-06-30 |
2021-05-17 | 2112.77 | 未披露 | 定期报告 | 2021-05-12 |
2021-04-22 | 2860.00 | 未披露 | 定期报告 | 2021-04-22 |
2021-04-22 | 2839.40 | 9.62 | 定期报告 | 2021-04-12 |
2021-05-17 | 2051.74 | 9.62 |
更多>>
From December 31, 2020 to March 31, 2021
Conversion of Preferred Series J to common stock
Common shares issued upon conversion of notes payable
Common shares issued upon exercise of warrants
Issuance of common stock in public offering, net of cost
Issuance of common stock for research and development agreement
Issuance of common stock for services
Equity compensation to officers and board of directors
|
2021-03-31 |
2021-02-12 | 2063.80 | 未披露 | 定期报告 | 2021-02-11 |
GT Biopharma, Inc. effect a reverse stock split of common stock, at a ratio of 1-for-30. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024.
From June 30, 2023 to September 30, 2023
Issuance of common stock in settlement of accounts payable and accrued expenses
Issuance of common stock to an officer and a board member for services
From March 31, 2023 to June 30, 2023
Issuance of common shares in settlement of vendors payable
Issuance of common stock for exercise of Prefunded Warrants
From December 31, 2022 to March 31, 2023
Private placement of common stock
Issuance of common shares for services
Issuance of common shares in settlement of vendors payable
Common Stock offered 3,600,000 shares by the company
From December 31, 2021 to December 31, 2022
Issuance of common stock as equity compensation to consultants
Cancellation of common stock previously issued for services
Issuance of common stock in settlement of vendor payable
Common stock issued upon conversion of notes payable
Cancellation of common stock previously issued to prior CEO
Issuance of common stock as equity compensation to officers, employees, and board of directors
From June 30, 2022 to September 30, 2022
Equity compensation to officers, employees, and board of directors
Issuance of common shares in settlement of vendor payable
Equity compensation to consultants
From March 31, 2022 to June 30, 2022
Cancellation of common stock upon settlement with former officer
Equity compensation to officers, employees, and board of directors
Issuance of common shares for services
From December 31, 2021 to March 31, 2022
Cancellation of common stock
Issuance of common shares for common shares issuable
Issuance of common shares as equity compensation to officers, employees, and board of directors
Issuance of common shares for services
From December 31, 2020 to December 31, 2021
Conversion of Preferred Series J-1 to common stock
Common shares issued upon mandatory conversion of notes payable and accrued interest
Common shares issued upon exercise of warrants
Issuance of common stock in public offering, net of cost
Issuance of common stock for research and development agreement
Issuance of common stock for services
Equity compensation to officers, board of directors and employees
From June 30, 2021 to September 30, 2021
Common shares issued upon conversion of notes payable
Common shares issued upon exercise of warrants
Issuance of common stock for services
Equity compensation to officers and board of directors
From March 31, 2021 to June 30, 2021
Common shares issued upon conversion of notes payable
Common shares issued upon exercise of warrants
Issuance of common stock for services
Equity compensation to officers and board of directors
From December 31, 2020 to March 31, 2021
Conversion of Preferred Series J to common stock
Common shares issued upon conversion of notes payable
Common shares issued upon exercise of warrants
Issuance of common stock in public offering, net of cost
Issuance of common stock for research and development agreement
Issuance of common stock for services
Equity compensation to officers and board of directors